BeiGene
BGNE
#963
Rank
HK$155.62 B
Marketcap
HK$1,371
Share price
1.02%
Change (1 day)
-0.84%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -HK$130.42

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -HK$129.29. In 2022 the company made an earnings per share (EPS) of -HK$150.50 a decrease over its 2021 EPS that were of -HK$118.18.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-HK$130.42-13.34%
2022-HK$150.5027.35%
2021-HK$118.18-19.96%
2020-HK$147.6620.81%
2019-HK$122.2231.52%
2018-HK$92.93417.57%
2017-HK$17.96-37.16%
2016-HK$28.57158.95%
2015-HK$11.03

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-HK$7.77-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$2.10-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA